The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide - PubMed (original) (raw)

The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide

M W Radomski et al. Br J Pharmacol. 1987 Nov.

Abstract

1. The interactions between endothelium-derived nitric oxide (NO) and prostacyclin as inhibitors of platelet aggregation were examined. 2. Porcine aortic endothelial cells treated with indomethacin and stimulated with bradykinin (10-100 nM) released NO in quantities sufficient to account for the inhibition of platelet aggregation attributed to endothelium-derived relaxing factor (EDRF). 3. In the absence of indomethacin, stimulation of the cells with bradykinin (1-3 nM) released small amounts of prostacyclin and EDRF which synergistically inhibited platelet aggregation. 4. EDRF and authentic NO also caused disaggregation of platelets aggregated either with collagen or with U46619. 5. A reciprocal potentiation of both the anti- and the dis-aggregating activity was also observed between low concentrations of prostacyclin and authentic NO or EDRF released from endothelial cells. 6. It is likely that interactions between prostacyclin and NO released by the endothelium play a role in the homeostatic regulation of platelet-vessel wall interactions.

PubMed Disclaimer

Cited by

Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells.
Radomski MW, Palmer RM, Moncada S. Radomski MW, et al. Proc Natl Acad Sci U S A. 1990 Dec;87(24):10043-7. doi: 10.1073/pnas.87.24.10043. Proc Natl Acad Sci U S A. 1990. PMID: 1702214 Free PMC article.
Metabolism of glyceryl trinitrate to nitric oxide by endothelial cells and smooth muscle cells and its induction by Escherichia coli lipopolysaccharide.
Salvemini D, Mollace V, Pistelli A, Anggard E, Vane J. Salvemini D, et al. Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):982-6. doi: 10.1073/pnas.89.3.982. Proc Natl Acad Sci U S A. 1992. PMID: 1310543 Free PMC article.
Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP.
MacIntyre I, Zaidi M, Alam AS, Datta HK, Moonga BS, Lidbury PS, Hecker M, Vane JR. MacIntyre I, et al. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2936-40. doi: 10.1073/pnas.88.7.2936. Proc Natl Acad Sci U S A. 1991. PMID: 1849281 Free PMC article.
Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy.
Megson IL, Sogo N, Mazzei FA, Butler AR, Walton JC, Webb DJ. Megson IL, et al. Br J Pharmacol. 2000 Dec;131(7):1391-8. doi: 10.1038/sj.bjp.0703731. Br J Pharmacol. 2000. PMID: 11090112 Free PMC article.
Biocompatibility screening in cardiovascular implants.
Sigler M, Paul T, Grabitz RG. Sigler M, et al. Z Kardiol. 2005 Jun;94(6):383-91. doi: 10.1007/s00392-005-0231-4. Z Kardiol. 2005. PMID: 15940438 Review.

References

1. Prostaglandins. 1978 Mar;15(3):383-97 - PubMed
1. Br J Pharmacol. 1982 May;76(1):3-31 - PubMed
1. Prostaglandins. 1982 Apr;23(4):579-89 - PubMed
1. Thromb Res. 1983 May 15;30(4):383-9 - PubMed
1. Annu Rev Pharmacol Toxicol. 1984;24:175-97 - PubMed

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Miscellaneous
- NCI CPTAC Assay Portal

The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide - PubMed (original) (raw)